PanGen Biotech Inc. (KOSDAQ:222110)

CTI BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,052	1,430	45.4	838.28	8,901	8,139
Short-Term Investments	9,002	10,002	149.24	2	15,199	10,550
Cash & Short-Term Investments	11,054	11,432	194.64	840.28	24,100	18,689
Cash Growth	154.80%	5773.48%	-76.84%	-96.51%	28.95%	-23.29%
Accounts Receivable	2,879	2,959	2,208	689.81	1,089	535.34
Other Receivables	195.21	51.8	8.54	221.29	241.03	176.87
Receivables	3,188	3,261	2,330	974.1	1,393	775.21
Inventory	6,854	6,001	6,925	6,630	4,373	3,764
Prepaid Expenses	46.52	53.96	58.91	71.41	21.39	15.49
Other Current Assets	47.37	20.35	333.62	60.91	1,267	847.87
Total Current Assets	21,189	20,768	9,843	8,576	31,154	24,092
Property, Plant & Equipment	5,848	5,805	6,240	6,608	6,748	6,029
Long-Term Investments	-0	0	0	0	-0	0
Other Intangible Assets	763	785.13	879.93	269.63	313.41	271.58
Long-Term Deferred Charges	2,458	2,622	3,278	3,933	4,589	5,244
Other Long-Term Assets	649.04	564.14	501.5	1,287	473.47	673.02
Total Assets	30,907	30,545	20,741	20,674	43,277	36,309
Accounts Payable	317.77	423.33	298.82	255.48	381.91	296.57
Short-Term Debt	850.05	816.3	2,014	-	18,692	18,399
Current Portion of Leases	1.4	1.84	1.69	1.56	1.43	-
Other Current Liabilities	1,241	1,657	3,396	872.49	811.14	1,395
Total Current Liabilities	2,410	2,899	5,711	1,130	19,886	20,091
Long-Term Leases	0.39	0.39	2.24	3.93	5.49	-
Other Long-Term Liabilities	30	30	30	206.41	116.22	77.31
Total Liabilities	5,262	5,636	8,175	3,454	22,179	22,098
Common Stock	6,449	6,449	5,339	5,339	5,336	4,821
Additional Paid-In Capital	67,712	67,712	57,402	57,402	57,371	47,840
Retained Earnings	-49,217	-49,953	-50,876	-46,210	-42,062	-38,680
Comprehensive Income & Other	700.82	700.82	700.82	688.64	452.86	229.89
Total Common Equity	25,645	24,909	12,566	17,219	21,098	14,211
Shareholders' Equity	25,645	24,909	12,566	17,219	21,098	14,211
Total Liabilities & Equity	30,907	30,545	20,741	20,674	43,277	36,309
Total Debt	851.84	818.54	2,018	5.49	18,699	18,399
Net Cash (Debt)	10,202	10,614	-1,823	834.79	5,402	290.4
Net Cash Growth	356.16%	-	-	-84.55%	1760.05%	-95.84%
Net Cash Per Share	858.45	927.83	-170.60	78.21	528.69	30.13
Filing Date Shares Outstanding	12.9	12.9	10.68	10.68	10.67	9.64
Total Common Shares Outstanding	12.9	12.9	10.68	10.68	10.67	9.64
Working Capital	18,779	17,869	4,132	7,447	11,267	4,001
Book Value Per Share	1988.26	1931.18	1176.85	1612.67	1976.95	1473.91
Tangible Book Value	24,882	24,124	11,686	16,950	20,784	13,940
Tangible Book Value Per Share	1929.10	1870.31	1094.44	1587.42	1947.58	1445.75
Land	1,174	1,174	1,174	1,174	1,174	1,004
Buildings	3,909	3,909	3,909	3,909	3,909	3,456
Machinery	11,897	11,766	11,545	11,434	10,381	9,811
Construction In Progress	-	-	125.36	-	332.66	1.11

Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.